Blue Cross Blue Shield Improper Denials for Cancer Drug Treatments – Class Action Investigation

Blue Cross Blue Shield Improper Denials for Cancer Drug Treatments – Class Action Investigation

CSK&D is investigating reports that certain health insurance organizations operating under the Blue Cross Blue Shield (“BCBS”) federation may be improperly denying cancer patients insurance coverage for cancer drugs—including but not limited to Keytruda, Opdivo, and Rituxan—which may be covered under the patients’ policies.  Reports indicate that BCBS’ upper management employees instituted an enterprise-wide policy of denying coverage for these cancer medications—despite having no basis for doing so and in violation of the insureds’ rights under the insurance policies—in order to increase BCBS’ profits.

CSK&D is investigating whether this is a from-the-top scheme that pervades multiple organizations under the BCBS umbrella.  Improper denial of otherwise covered prescription drugs intended to treat cancer patients can serve no other purpose than to reduce payments and costs borne by the BCBS insurance organizations.  These improper prescription drug denials may result in cancer patients not receiving proper and timely treatments, which can lead to progression of illness or untimely death.

If you or someone you know has experience with a BCBS organization denying coverage for cancer-related drugs, or if you have firsthand knowledge of BCBS’s practices in doing so, please contact the lawyers listed below